Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Novel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolution.

Jonsson VD, Blakely CM, Lin L, Asthana S, Matni N, Olivas V, Pazarentzos E, Gubens MA, Bastian BC, Taylor BS, Doyle JC, Bivona TG.

Sci Rep. 2017 Mar 13;7:44206. doi: 10.1038/srep44206.

2.

The transporter and permeability interactions of asymmetric dimethylarginine (ADMA) and L-arginine with the human blood-brain barrier in vitro.

Watson CP, Pazarentzos E, Fidanboylu M, Padilla B, Brown R, Thomas SA.

Brain Res. 2016 Oct 1;1648(Pt A):232-242. doi: 10.1016/j.brainres.2016.07.026. Epub 2016 Jul 16.

3.

RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer.

Hrustanovic G, Olivas V, Pazarentzos E, Tulpule A, Asthana S, Blakely CM, Okimoto RA, Lin L, Neel DS, Sabnis A, Flanagan J, Chan E, Varella-Garcia M, Aisner DL, Vaishnavi A, Ou SH, Collisson EA, Ichihara E, Mack PC, Lovly CM, Karachaliou N, Rosell R, Riess JW, Doebele RC, Bivona TG.

Nat Med. 2015 Sep;21(9):1038-47. doi: 10.1038/nm.3930. Epub 2015 Aug 24.

4.

Oncogenic activation of the PI3-kinase p110β isoform via the tumor-derived PIK3Cβ(D1067V) kinase domain mutation.

Pazarentzos E, Giannikopoulos P, Hrustanovic G, St John J, Olivas VR, Gubens MA, Balassanian R, Weissman J, Polkinghorn W, Bivona TG.

Oncogene. 2016 Mar 3;35(9):1198-205. doi: 10.1038/onc.2015.173. Epub 2015 May 18.

PMID:
25982275
5.

AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas.

Elkabets M, Pazarentzos E, Juric D, Sheng Q, Pelossof RA, Brook S, Benzaken AO, Rodon J, Morse N, Yan JJ, Liu M, Das R, Chen Y, Tam A, Wang H, Liang J, Gurski JM, Kerr DA, Rosell R, Teixidó C, Huang A, Ghossein RA, Rosen N, Bivona TG, Scaltriti M, Baselga J.

Cancer Cell. 2015 Apr 13;27(4):533-46. doi: 10.1016/j.ccell.2015.03.010.

6.

NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer.

Blakely CM, Pazarentzos E, Olivas V, Asthana S, Yan JJ, Tan I, Hrustanovic G, Chan E, Lin L, Neel DS, Newton W, Bobb KL, Fouts TR, Meshulam J, Gubens MA, Jablons DM, Johnson JR, Bandyopadhyay S, Krogan NJ, Bivona TG.

Cell Rep. 2015 Apr 7;11(1):98-110. doi: 10.1016/j.celrep.2015.03.012. Epub 2015 Apr 2.

7.

Adaptive stress signaling in targeted cancer therapy resistance.

Pazarentzos E, Bivona TG.

Oncogene. 2015 Nov 5;34(45):5599-606. doi: 10.1038/onc.2015.26. Epub 2015 Feb 23. Review.

8.

The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.

Lin L, Sabnis AJ, Chan E, Olivas V, Cade L, Pazarentzos E, Asthana S, Neel D, Yan JJ, Lu X, Pham L, Wang MM, Karachaliou N, Cao MG, Manzano JL, Ramirez JL, Torres JM, Buttitta F, Rudin CM, Collisson EA, Algazi A, Robinson E, Osman I, Muñoz-Couselo E, Cortes J, Frederick DT, Cooper ZA, McMahon M, Marchetti A, Rosell R, Flaherty KT, Wargo JA, Bivona TG.

Nat Genet. 2015 Mar;47(3):250-6. doi: 10.1038/ng.3218. Epub 2015 Feb 9.

9.

Stefan Grimm, 1963-2014, a tragic loss for the scientific community.

Mahul-Mellier AL, Huc L, Lemarié A, Irshad S, Hwang M, Datler C, Pazarentzos E.

Cell Death Differ. 2015 Feb;22(2):247. doi: 10.1038/cdd.2014.196. No abstract available.

10.

IκΒα inhibits apoptosis at the outer mitochondrial membrane independently of NF-κB retention.

Pazarentzos E, Mahul-Mellier AL, Datler C, Chaisaklert W, Hwang MS, Kroon J, Qize D, Osborne F, Al-Rubaish A, Al-Ali A, Mazarakis ND, Aboagye EO, Grimm S.

EMBO J. 2014 Dec 1;33(23):2814-28. doi: 10.15252/embj.201488183. Epub 2014 Oct 31.

11.

Anticancer gene transfer for cancer gene therapy.

Pazarentzos E, Mazarakis ND.

Adv Exp Med Biol. 2014;818:255-80. doi: 10.1007/978-1-4471-6458-6_13. Review.

PMID:
25001541
12.

Mitochondrial Ca(2+) influx targets cardiolipin to disintegrate respiratory chain complex II for cell death induction.

Hwang MS, Schwall CT, Pazarentzos E, Datler C, Alder NN, Grimm S.

Cell Death Differ. 2014 Nov;21(11):1733-45. doi: 10.1038/cdd.2014.84. Epub 2014 Jun 20.

13.

The anticancer gene ORCTL3 targets stearoyl-CoA desaturase-1 for tumour-specific apoptosis.

AbuAli G, Chaisaklert W, Stelloo E, Pazarentzos E, Hwang MS, Qize D, Harding SV, Al-Rubaish A, Alzahrani AJ, Al-Ali A, Sanders TA, Aboagye EO, Grimm S.

Oncogene. 2015 Mar 26;34(13):1718-28. doi: 10.1038/onc.2014.93. Epub 2014 Apr 28.

14.

CKMT1 regulates the mitochondrial permeability transition pore in a process that provides evidence for alternative forms of the complex.

Datler C, Pazarentzos E, Mahul-Mellier AL, Chaisaklert W, Hwang MS, Osborne F, Grimm S.

J Cell Sci. 2014 Apr 15;127(Pt 8):1816-28. doi: 10.1242/jcs.140467. Epub 2014 Feb 12.

15.

Dose-dependent neuroprotection of VEGF₁₆₅ in Huntington's disease striatum.

Ellison SM, Trabalza A, Tisato V, Pazarentzos E, Lee S, Papadaki V, Goniotaki D, Morgan S, Mirzaei N, Mazarakis ND.

Mol Ther. 2013 Oct;21(10):1862-75. doi: 10.1038/mt.2013.132. Epub 2013 Jun 25.

16.

De-ubiquitinating proteases USP2a and USP2c cause apoptosis by stabilising RIP1.

Mahul-Mellier AL, Datler C, Pazarentzos E, Lin B, Chaisaklert W, Abuali G, Grimm S.

Biochim Biophys Acta. 2012 Aug;1823(8):1353-65. doi: 10.1016/j.bbamcr.2012.05.022. Epub 2012 May 30.

17.

De-ubiquitinating protease USP2a targets RIP1 and TRAF2 to mediate cell death by TNF.

Mahul-Mellier AL, Pazarentzos E, Datler C, Iwasawa R, AbuAli G, Lin B, Grimm S.

Cell Death Differ. 2012 May;19(5):891-9. doi: 10.1038/cdd.2011.185. Epub 2011 Dec 16.

18.

Fis1 and Bap31 bridge the mitochondria-ER interface to establish a platform for apoptosis induction.

Iwasawa R, Mahul-Mellier AL, Datler C, Pazarentzos E, Grimm S.

EMBO J. 2011 Feb 2;30(3):556-68. doi: 10.1038/emboj.2010.346. Epub 2010 Dec 24.

19.

Specific disintegration of complex II succinate:ubiquinone oxidoreductase links pH changes to oxidative stress for apoptosis induction.

Lemarie A, Huc L, Pazarentzos E, Mahul-Mellier AL, Grimm S.

Cell Death Differ. 2011 Feb;18(2):338-49. doi: 10.1038/cdd.2010.93. Epub 2010 Aug 13.

Supplemental Content

Loading ...
Support Center